Norwegian blood samples reveal E. coli variants that are resistant to several antibiotics

NewsGuard 100/100 Score

One out of ten E. coli samples contained variants that are resistant to several kinds of antibiotics, a new analysis on Norwegian blood samples revealed. The proportion of multi-resistant E. coli bacteria doubled from 2002-2009 to 2010-2017.

Researchers at the University of Oslo have analyzed 3200 blood samples from patients in Norway with E. coli (an abbreviation for Escherichia coli). They examined whether the bacteria were multi-resistant, meaning that several types of antibiotics do not work against them.

From 2002 and over the following 8 years, every twentieth sample was shown to be resistant to antibiotics. When they analysed the samples from the next 8 years - up until 2018 - they found multi-resistant bacteria in every tenth sample. In other words, the proportion of multi-resistant bacteria had doubled.

Their research has recently been published in The Lancet Microbe.

Treating E. coli can become difficult

It is important to understand how and why antibiotic resistance is increasing and making infections more difficult to treat. As in the case of many types of infections, the youngest and eldest run the greatest risk of falling seriously ill and we must have antibiotics that can treat these bacteria. That is why it is so important to monitor the development of antibiotic resistance. This set of data provides us with a deeper understanding of the current situation, says Rebecca Gladstone.

She is a postdoctoral fellow at the Department of Basic Medical Sciences and has conducted the research on the Norwegian samples together with professor Jukka Corander.

In the study, the researchers looked at samples of E. coli that had entered the blood from the intestines, where antibiotics play an important role. E. coli is for example a common cause of urinary tract infections.

E. coli also finds its way into the stomach of many people via food that has not been appropriately cooked. E. coli is present in the intestines of both humans and animals and does not normally cause any harm. However, some groups of E. coli can cause serious infections, especially in people suffering from underlying diseases or a weak immune system.

Last year, a child died following complications caused by E. coli bacteria. There was a major outbreak of E. coli infections in Norway in 2006, when 18 people fell seriously ill after eating a type of cured, pork sausage. One child died.

Norway has a lower prevalence of multi-resistant E. coli

The level of multi-resistant E. coli bacteria in Norway is not a cause for alarm just now, explains Gladstone, who emphasises that Norway is doing better on this score than a number of other countries in Europe.

- Nevertheless, we must continue to monitor developments carefully so that we are prepared if the situation worsens. We expect that antibiotic resistance will increase as time goes on.

Faster spread of multi-resistant E. coli in Great Britain

The researchers in Oslo collaborated with scientists in Great Britain in order to compare the development of antibiotic resistance in the two countries. In Great Britain, there is a faster spread of E. coli bacteria that are resistant to antibiotics.

- This may be due to the fact that the population is larger in Great Britain, but also to differences in the type and the use of antibiotics. In Norway, the use of antibiotics has been more strictly controlled than in a number of other countries. In addition, we found differences between Norway and Great Britain as regards the variants of E. coli causing infections in the blood. In the initial phase, Norway had one variant in particular that dominated and outcompeted the other more multi-resistant variants, says the postdoctoral researcher.
 

Source:
Journal reference:

Gladstone, R. A., et al. (2021) Emergence and dissemination of antimicrobial resistance in Escherichia coli causing bloodstream infections in Norway in 2002–17: a nationwide, longitudinal, microbial population genomic study. The Lancet Microbe. doi.org/10.1016/S2666-5247(21)00031-8.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Repurposed nasal antibiotic neomycin shows promise in preventing and treating respiratory viral infections